InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,477.90
(
0.16%
)
US TECH 100
19,131.60
(
-0.23%
)
Dow Jones
39,127.80
(
0.04%
)
Brent Oil
84.33
(
-0.17%
)
Bitcoin
60,910.51
(
0.16%
)
Post# of 252389
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119931
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 93563

Wednesday, 09/26/2012 9:14:12 AM

Wednesday, September 26, 2012 9:14:12 AM

Post# of 252389
This physician survey is bullish for ABT, PFE/AMGN, JNJ/MRK, and (paradoxically) MNTA:

http://finance.yahoo.com/news/rheumatologists-gastroenterologists-reluctant-prescribe-biosimilars-130000415.html

BioTrends Research Group, one of the world’s leading research and advisory firms for specialized biopharmaceutical issues, finds that surveyed gastroenterologists and rheumatologists in the United States and Europe have a low or medium-low likelihood of prescribing a biosimilar for an indication in which it has not been clinically tested.

The survey is bullish for ABT, PFE/AMGN, and JNJ/MRK because they sell the three leading biologics for RA (Humira, Enbrel, and Remicade, respectively). It is bullish for MNTA because an interchangeable FoB in the US for one of the above drugs will not have to be prescribed in order to be used.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up